O Orexo AB
O
Abierto
20.9 8.52
Resumen
Variación precio
24h
Mínimo
19.24
Máximo
20.95
Ingresos | 41M -75M |
|---|---|
Ventas | 1.7M 5M |
BPA | -3.812 |
Margen de beneficios | -1,500 |
Empleados | 65 |
EBITDA | 206M -66M |
Próximas Ganancias | 16 jul 2026 |
|---|
Capitalización Mercado | -35M 665M |
|---|---|
Apertura anterior | 12.38 |
Cierre anterior | 20.9 |
Orexo AB Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
